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& INTRODUCTION
Viral hepatitis is a public health problem in Brazil and
worldwide. According to the World Health Organization
(WHO), 2 billion people have had contact with the hepatitis
B virus (HBV); approximately 5% of these individuals are
considered carriers (1).
The risk of chronicity after infection is 90% in the
newborns of mothers with positive hepatitis B early antigen
(HBeAg), 25 to 30% in children under 5 years of age, and
less than 5% in adults (2). Chronic carriers have an increased
risk (15 to 40%) of developing cirrhosis, hepatic decom-
pensation, and hepatocellular carcinoma, resulting in 1
million deaths each year (3).
The most effective hepatitis B preventive measure is
vaccination. Since 1998, a policy of universal vaccination has
been implemented for children younger than 1 year in
Brazil. The policy was subsequently extended to people
younger than 20 years (4). Vaccination was also extended to
vulnerable populations (e.g., injected drug users or health-
care workers) in 2001 and to people up to 29 years of age in
2010 (5). It is estimated that 75% of the under-29 population
is vaccinated (6).
Because HBV carriers are the source of infection and
chronic hepatitis B is a major cause of cirrhosis and
hepatocellular carcinoma, it is important to understand the
incidence, prevalence, and chronification associated with
HBV infection (7).
The objective of this study was to describe the clinical
outcomes of patients with confirmed acute hepatitis B
(AHB) in the South region of Brazil in the city of Porto
Alegre from 1999 to 2007.
& PATIENTS AND METHODS
This retrospective-prospective cohort study was based on
secondary data (retrospective data) obtained from the
Information System for Notifiable Diseases (SINAN) and
primary data collected from patients who completed
structured and semi-structured questionnaires (prospective
data).
A case was defined as any individual reported to SINAN
in Porto Alegre, a city of 1.5 million inhabitants, from
January 1999 to December 2007, and who had positive
HBsAg and positive immunoglobulin M antibody to the
hepatitis B core antigen (anti-HBc IgM). The patients were
contacted at their addresses and phone numbers, and the
records of individuals whom we were unable to find were
checked through the Mortality Information System or the
Health Care Unit registers.
After signing informed consent forms, the patients
answered questionnaires evaluating epidemiologic data,
the risk factors for hepatitis B acquisition and their
participation in consultation and preventive measurements
(i.e., vaccination). They were asked to supply copies of
laboratory tests performed at least 6 months after their AHB
diagnoses. If no information could be obtained, serological
tests were performed in a Public Health Service unit.
Patients were considered to have resolved hepatitis B if
they had negative HBsAg and positive antibodies to the
hepatitis B surface antigen (anti-HBs) after 6 months and, in
cases of chronic carriers, if they presented with positive
HBsAg in the same period (8).
To determine the number of coinfected patients, the
authors examined notification forms with information
related to coinfection with hepatitis C virus (HCV) and
human immunodeficiency virus (HIV).
This study was approved by the Ethics Committee of the
Universidade Federal de Cieˆncias da Sau´de de Porto Alegre.
In the statistical analysis, Pearson’s Chi-squared test was
used, with a 5% level of significance.
& RESULTS
Between 1999 and 2007, 103 confirmed cases of AHB were
reported to SINAN in Porto Alegre: 67 (65%) patients were
male, and 77 (74.8%) were aged between 20 and 49 years.
Of the 103 eligible patients, it was possible to identify
outcomes in 78 (75.7%) cases: 56 (71.8%) were considered
resolved; 11 (14.1%) became chronic carriers; and 11 (14.1%)
died. Four (36.4%) of the 11 deaths (5.1% of the 78 evaluated
patients) resulted from fulminant hepatitis.
Hepatitis became chronic in patients older than 22 years: 8
of these patients (72.7%) were between 20- and 49-years-old,
and 3 (27.3%) were over 50-years-old. The Caucasian race
was prevalent, and female patients became chronic carriers
more often than males.
Seventeen (16.5%) of the 103 reported patients had
associated coinfections: 12 (70.6%) had HIV; 4 (23.5%) had
HIV/HCV; and 1 (5.9%) had HCV. There was no association
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between the type of coinfection and patient outcomes,
chronicity, resolutions or deaths (p = 0.747). Two of the
patients who became chronic carriers were coinfected, 1
with HIV and 1 with HIV/HCV.
& DISCUSSION
Since the early 70s, several published studies have
evaluated the chronicity of AHB in adult patients (Table 1)
and shown an evolution to chronicity of up to 12% (9-25). A
meta-analysis of 10 studies with adult heterogeneous
populations, without adjusting for potential differences
between them, showed that the risk of chronicity was higher
than 10% in 2 studies, 5% in 1 and less than 5% in 7 (7).
Note that the chronicity in this study was high (14.1%)
compared to the literature. This discrepancy could most
likely be explained by the fact that the evolution to
chronicity is inversely proportional to the age at which
infection occurs (16). For example, some authors have
reported that approximately 10% of patients who become
infected with HBV as adults would not clear HBsAg after 6
months (21). As shown in our sample, all the patients were
older than 22 years, which could justify a higher chronicity.
Note that other studies have also observed high frequencies
of chronicity (10,15,17). Several factors are associated with
the increased risk of chronic HBV infection, including male
gender, various causes of immune deficiency, genome
variations, and genetic, hormonal and nutritional factors (7).
Differences in chronicity can also be explained by the
manner in which it was calculated. In the present study, the
evolution to chronicity was calculated based on patients
who had complete follow-ups, similar to other studies
(15,24). However, some authors did not specify whether
there were losses in the follow-up (17) or if they calculated
the progression to chronicity based on the total number of
patients or only those with completed follow-ups (11). The
results of the present study could be overestimated because
some patients were lost to follow-up.
Regarding deaths, it is relevant that 5.1% of patients (4 of
78) died of causes related to fulminant hepatitis. Clearly,
this result is most likely overestimated by the under-
reporting of AHB.
Implementing the HBV vaccination over the last 30 years
in several countries, such as the United States in 1981,
Taiwan in 1984 and Brazil in 1998, has promoted a change in
patient outcomes (13,18,26,27).
Of the AHB patients, 77 (74.8%) were aged between 20
and 49 years; this age range is not included in the National
Immunization Program. Our findings suggest the impor-
tance of revising the inclusion criteria used in the vaccina-
tion schedule currently used in Brazil.
Regarding ethnicity, the Caucasian race was prevalent.
Regarding gender, female patients were more likely to
become chronic carriers, although this difference was not
statistically significant. This result was not in alignment
with other studies, which have reported a higher evolution
to chronicity in male individuals (28,29,30).
Regarding the 17 coinfected patients, 12 (70.6%) had HIV,
4 had HIV/HCV, and 1 had HCV. HBV/HIV coinfection
occurs in many patients, and it is explained by the common
routes of transmission for these 2 viruses, primarily sexual,
parenteral and vertical (31). A study conducted in Porto
Alegre involving 587 HIV patients showed that 14 of 306
(4.6%) had positive HBsAg (32).
Note that 2 patients who became chronic carriers were
coinfected. Literature reports suggest that worse outcomes
are more frequent in coinfected patients (33).
The abovementioned results suggest the utmost impor-
tance of control measures and epidemiological assessments
of HBV patients because in the evaluated population, there
were high levels of chronicity and mortality related to liver
injury. Effective actions, such as universal vaccination,
break the transmission chain of HBV. The appropriate
follow-up of patients and their contacts (home and/or
sexual) is essential for improving the well-being of our
population.
& AUTHOR CONTRIBUTIONS
Souza LA was responsible for all the phases of the study from conception to
the manuscript draft. Mattos AA was responsible for the general
coordination of the study, draft and critical review of the manuscript.
Fiorini M and Ribeiro P were responsible for collecting the data and
organizing the database. Tovo CV participated in drafting and critical
review of the manuscript.
Table 1 - Studies that have assessed the chronicity of acute hepatitis B in adult populations.
Reference Author N Chronicity (%) Assessed population
9 Barker 172 7.0 Prisoners
10 Beasley 37 2.7 Students: Taiwan
11 Ferraz 357 1.7 Acute hepatitis B: Brazil
12 Gimeno 63 0 Drug addicts
13 Hoofnagle 149 4.7 Prisoners
14 Kent 35 0 Acupuncture
15 Kuruuzum 240 4.6 Acute hepatitis B: Turkey
16 Lavarini 150 4.0 Acute hepatitis B: Italy
17 McMahon 48 10.4 Eskimos (Alaska)
18 Rinker 28 0 Women who received contaminated blood
19 Roumeliotou* 13 0 Women with heterosexual contact
20 Roumeliotou*
21 Schomerus* 58 12.0 Acute hepatitis B: Germany
22 Wiedmann*
19 Roumeliotou* 507 0.2 Acute hepatitis B: Greece
23 Tassopoulos*
24 Tassopoulos*
25 Wands 17 0 Oncologic staff
*Studies published on the same population. Only data from studies with the greatest number of individuals were considered.
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